Aktienanalyse zu Vanda Pharmaceuticals Inc (VNDA)VNDAVanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Vanda Pharmaceuticals Inc is currently a hold. The stock is priced at $5.29, significantly below its analyst price target of $14.13, suggesting potential for growth. However, the company has reported a substantial net loss of $62.51 million in Q2 2026, which raises concerns about its profitability and future cash flow. Additionally, the RSI is at 46.31, indicating a neutral momentum, and insider selling has increased by 972.59%, which may signal a lack of confidence among insiders. Given these mixed signals, it may be prudent to wait for clearer signs of recovery before making a purchase.

6 analysts cover VNDA: 5 rate it Buy, 0 Hold and 1 Sell. The average price target is 13.63.